iii) Conduct clinical trials on KRAS-mutant patients: FOLFIRI plus cetuximab may be the first-line regimen for patients with KRAS exon 2 wild-type colorectal cancer, according to a phase III clinical trial (25). Here, KRAS is linked to colorectal cancer.